INTRODUCTION {#Sec1}
============

While initial reports did not highlight such symptoms, recent data from several countries suggest that SARS-CoV-2-positive inpatients experienced loss of smell and/or taste.^[@CR1],\ [@CR2]^ In a retrospective web-based study of outpatients who had attended one of three emerging diseases center in France, the combination of hyposmia and hypogeusia had moderate sensitivity (42%) and high specificity (95%) for the identification of SARS-CoV-2-positive patients.^[@CR2]^ While loss of smell or taste could be a key symptom to guide early identification of new cases in primary care, the extent to which participants in this study were representative of primary care patients is unclear. To address this limitation, we conducted a study involving primary care patients in France.

METHODS {#Sec2}
=======

This preliminary cross-sectional study was conducted between March 24, 2020, and April 14, 2020, in two clinical laboratories in Lyon (France) to which general practitioners (GPs) refer patients with a suspicion of COVID-19 for a nasopharyngeal smear (RT-PCR).

Before undergoing the test, the patients responded to a pre-formatted questionnaire about their symptoms, built on previous literature^[@CR3],\ [@CR4]^ and expert opinion. Data were analyzed using Stata 15, adjusting for clustering within the two laboratories. We examined the univariate and multivariate association between smell and/or taste disorders and a positive SARS-CoV-2 test, adjusting for all the other symptoms frequently reported by the patients. We also examined the performance of these smell and taste symptoms in predicting a SARS-CoV-2-positive test.

RESULTS {#Sec3}
=======

A total of 816 consecutively recruited patients were included in the analysis; 532 (65%) were women. The median age was 45 (interquartile range, 28; min--max, 4--92); 302 (37%) were healthcare professionals. Cough and dry throat were the most frequently reported symptoms (Table [1](#Tab1){ref-type="table"}). Patients who tested positive for SARS-CoV-2 (*n* = 198 (24%)) reported loss of smell or taste significantly more often than patients who tested negative (Table [2](#Tab2){ref-type="table"}). Smell or taste disorders were significantly associated with positive RT-PCR with an adjusted OR = 6.3 (95% CI, 5.2--7.5) in this primary care population with a high pre-test probability of COVID-19.Table 1Proportion of Symptoms Reported by Patients (*N* = 816)Symptoms*N* (%)Anosmia or hyposmia156 (19.1)Ageusia or hypogeusia188 (23.0)Fever\*366 (44.9)Asthenia115 (14.1)Headache\*359 (44.1)Cough450 (55.2)Dyspnea143 (17.5)Chest pain\*164 (20.1)Myalgia166 (20.3)Diarrhea\*174 (21.4)Dry nose\*173 (21.2)Stuffy nose\*211 (25.9)Dry throat\*384 (47.1)Sore throat54 (6.6)\*Data missing for 1 patientTable 2Association Between Smell and/or Taste Disorders, and Positivity of the SARS-CoV-2 RT-PCR TestSymptomsOverall (*N* = 816), *n* (%)Patients with a positive test (*N* = 198), *n* (%)Patients with a negative test (*N* = 618), *n* (%)Crude OR (95% CI)^1^*p* value^1^Adjusted OR (95% CI)^2^Adjusted *p* value^2^Sensitivity (%)Specificity (%)ROC area (95% CI)Smell disorder ^3^156 (19.1)82 (41.4)74 (12.0)5.2 (4.3-6.3)\< 0.0016.3 (5.8--6.9)\< 0.00141.488.00.65 (0.61--0.68)Taste disorder ^4^188 (23.0)92 (46.5)96 (15.5)4.7 (3.4--6.6)\< 0.0014.9 (3.2--7.5)\< 0.00146.584.50.66 (0.62--0.69)Smell *and* taste disorder^3,4^102 (12.5)58 (29.3)44 (7.1)5.4 (2.9--10.1)\< 0.0015.9 (3.2--11.1)\< 0.00129.392.90.61 (0.58--0.64)Smell *or* taste disorder^3,4^242 (29.7)116 (58.6)126 (20.4)5.5 (4.6--6.7)\< 0.0016.3 (5.2--7.5)\< 0.00158.679.60.69 (0.65--0.73)^1^Univariate logistic regression (adjusted for clustering within labs)^2^Multivariate logistic regression (adjusted for clustering within labs, gender, age group, and patient reporting of fever, asthenia, headache, cough, dyspnea, chest pain, myalgia, diarrhea, dry nose, stuffy nose, dry throat, sore throat)^3^Anosmia or hyposmia^4^Ageusia or hypogeusia

DISCUSSION {#Sec4}
==========

The tropism of SARS-CoV-2 for the nerves of the ear, nose, and throat system^[@CR5]^ may explain the relatively high proportion of SARS-CoV-2 patients suffering from smell and taste disorders, compared with patients suffering from upper respiratory tract infections with other viruses.

In this epidemic context, a simple clinical screening tool could be very efficient. Smell and taste disorders seem to be very specific to SARS-CoV-2 infection. This is a key finding to inform triage strategies and early isolation of new clusters of infection through primary care. The high specificity of these symptoms means GPs could rely on them to affirm a diagnosis of COVID-19, referring only patients with low pre-test probability (i.e., with non-specific symptoms) to RT-PCR screening. This could be a strategy to consider in lower resource settings, when RT-PCR testing is not widely available, or lack of protective gear would lead to excessive risk of contamination for the caregiver performing the test.

Our study was initiated after the first media reports of a possible link between anosmia and COVID-19. This may have prompted patients to over-report these symptoms, thus affecting their prevalence in our sample. Since patients were asked about the symptoms before receiving the results of their test, this limits the repercussions of this potential reporting bias on our measures of association.

Future studies should explore the diagnostic performance of various combinations of symptoms (i.e., anosmia and ageusia, anosmia without rhinitis, anosmia with nasal dryness...) to increase the specificity of the clinical picture. In accordance with Wynants et al.'s recommendations,^[@CR6]^ these studies should be performed with a representative dataset (i.e., primary care--based sample), an adequate description of the study population and external validation of the diagnostic tool.

In conclusion, our study shows that smell and taste disorders are common in primary care patients with SARS-CoV-2 infection. These symptoms might represent the first step to build a relatively simple clinical screening tool to use in primary care in an epidemic context. Once confinement measures are lifted, our data could further inform triage and early identification of new clusters of cases through primary care.
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